Application of PTPRM in the treatment and / or prevention of septic cardiomyopathy

By overexpressing PTPRM in septic cardiomyopathy, the lack of effective treatments in existing technologies has been addressed, resulting in improved survival rates and cardiac function.

CN122124244APending Publication Date: 2026-06-02GENERAL HOSPITAL OF PLA
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
GENERAL HOSPITAL OF PLA
Filing Date
2026-02-02
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

The relationship between PTPRM and septic cardiomyopathy has not been reported in the current technology, and there is a lack of effective treatment and prevention methods.

Method used

Using PTPRM as a target, products for the treatment and prevention of septic cardiomyopathy are prepared by enhancing the function or expression level of PTPRM through reagents that express or overexpress PTPRM, including vectors, factors that promote PTPRM gene transcription, or PTPRM protein agonists.

Benefits of technology

It significantly improves the survival rate of septic mice, reverses sepsis-induced cardiac damage, improves the function of the left and right ventricles and myocardium, reduces the expression of cardiac troponin, and effectively treats septic cardiomyopathy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122124244A_ABST
    Figure CN122124244A_ABST
Patent Text Reader

Abstract

This invention relates to the field of biomedical technology, specifically to the application of PTPRM in the treatment and / or prevention of septic cardiomyopathy. This application found that the expression level of PTPRM was significantly reduced in the cardiac tissue of a CLP model, and further verified that overexpression of PTPRM significantly improved the survival rate of the CLP model. Furthermore, the reduction in PAT caused by CLP modeling, as well as the increases in RVDFW, RVSFW, LVSFW, LVDFW, IVS-s, and IVS-d, were also improved. In addition, overexpression of PTPRM can also reduce the expression level of cardiac troponin (cTNT) and right ventricular wall thickness. Therefore, PTPRM can be used as a target for the treatment of septic cardiomyopathy.
Need to check novelty before this filing date? Find Prior Art